Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Crestor Should Be Withdrawn For Safety Risks – Public Citizen

Executive Summary

Public Citizen is citing AstraZeneca's marketing efforts for Crestor as one reason FDA should rapidly withdraw the statin

You may also be interested in...



Crestor European Label Changes Prompt FDA Public Health Advisory

FDA is stressing that physicians should carefully read labeling for AstraZeneca's Crestor after changes to the statin's European label

Crestor European Label Changes Prompt FDA Public Health Advisory

FDA is stressing that physicians should carefully read labeling for AstraZeneca's Crestor after changes to the statin's European label

AstraZeneca Defends Crestor; Public Citizen Renews Call For Withdrawal

The post-marketing safety profile of Crestor is in line with the overall experience of the statin category, AstraZeneca said May 19 in response to a renewed request from Public Citizen for withdrawal of the cholesterol-lowering drug

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043465

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel